GENFIT (NASDAQ:GNFT) Shares Up 1.9% - Time to Buy?

Key Points

• GENFIT's stock price increased by 1.9% during trading, reaching a high of $4.41 before closing at $4.24, despite a significant decrease in trading volume.
• Analysts are mixed on GENFIT, with a consensus "Hold" rating and an average target price of $7.00, while one analyst rates it a Buy and another a Sell.
• Institutional interest has grown, with OLD Mission Capital LLC acquiring 22,238 shares valued at approximately $76,000, indicating potential confidence in the company's prospects.

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report)'s stock price shot up 1.9% during trading on Friday . The stock traded as high as $4.41 and last traded at $4.24. 2,591 shares traded hands during trading, a decline of 76% from the average session volume of 10,873 shares. The stock had previously closed at $4.16.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Weiss Ratings restated a "sell (d)" rating on shares of GENFIT in a report on Tuesday. HC Wainwright cut their price objective on GENFIT from $9.00 to $7.00 and set a "buy" rating on the stock in a research report on Wednesday, September 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, GENFIT has a consensus rating of "Hold" and an average target price of $7.00.

GENFIT Stock Up 1.9%

The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.09. The stock's 50 day moving average is $4.04 and its 200-day moving average is $3.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC acquired a new position in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is owned by hedge funds and other institutional investors.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.